Terms: = Breast cancer AND TPM3, ENSG00000143549, 7170 AND Treatment
4 results:
1. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract] [Full Text] [Related]
2. Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the treatment of Androgen Receptor-positive Prostate and breast cancers.
Tien AH; Sadar MD
Mol Cancer Ther; 2022 Feb; 21(2):294-309. PubMed ID: 34815359
[TBL] [Abstract] [Full Text] [Related]
3. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic breast cancer Patients Treated with Everolimus.
Duan F; Song C; Ma Y; Jiang K; Xu F; Bi X; Huang J; Hong R; Huang Z; Lu Q; Yuan Z; Wang S; Xia W
Drug Des Devel Ther; 2021; 15():3463-3473. PubMed ID: 34408400
[TBL] [Abstract] [Full Text] [Related]
4. From morphological to molecular diagnosis of soft tissue tumors.
Miettinen M
Adv Exp Med Biol; 2006; 587():99-113. PubMed ID: 17163160
[TBL] [Abstract] [Full Text] [Related]
